EDUARDO FERREIRA BORBA NETO

(Fonte: Lattes)
Índice h a partir de 2011
26
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Clínica Médica, Faculdade de Medicina - Docente
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina

Filtros

Mostrar mais
Limpar filtros

Configurações

Revista / Livro: Annals of the Rheumatic Diseases ×

Resultados de Busca

Agora exibindo 1 - 10 de 11
  • article 89 Citação(ões) na Scopus
    Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL)
    (2017) UGARTE-GIL, Manuel Francisco; WOJDYLA, Daniel; PONS-ESTEL, Guillermo J.; CATOGGIO, Luis J.; DRENKARD, Cristina; SARANO, Judith; BERBOTTO, Guillermo A.; BORBA, Eduardo F.; SATO, Emilia Inoue; BRENOL, Joao C. Tavares; URIBE, Oscar; GOMEZ, Luis A. Ramirez; GUIBERT-TOLEDANO, Marlene; MASSARDO, Loreto; CARDIEL, Mario H.; SILVEIRA, Luis H.; CHACON-DIAZ, Rosa; ALARCON, Graciela S.; PONS-ESTEL, Bernardo A.
    Objective To evaluate disease activity statuses' (DAS') impact on systemic lupus erythematosus (SLE) outcomes. Materials and methods Four DAS were defined: remission off-therapy: SLE Disease Activity Index (SLEDAI)=0, no prednisone or immunosuppressive drugs (IS); remission on-therapy: SLEDAI=0, prednisone <= 5 mg/day and/or IS (maintenance); low (L) DAS: SLEDAI <= 4, prednisone <= 7.5 mg/day and/or IS (maintenance); non-optimally controlled: SLEDAI >4 and/or prednisone >7.5 mg/day and/or IS (induction). Antimalarials were allowed in all. Predefined outcomes were mortality, new damage (increase of at least one Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index (SDI) point) and severe new damage (increase of at least 3 SDI points). Univariable and multivariable Cox regression models were performed to define the impact of DAS, as time-dependent variable, on these outcomes. Results 1350 patients were included, 79 died during follow-up, 606 presented new and 177 severe new damage. In multivariable analyses, remission (on/off-therapy) was associated with a lower risk of new (HR 0.60; 95% CI 0.43 to 0.85), and of severe new damage (HR 0.32; 95% CI 0.15 to 0.68); low disease activity status (LDAS) was associated with a lower risk of new damage (HR 0.66; 95% CI 0.48 to 0.93) compared with non-optimally controlled. No significant effect on mortality was observed. Conclusions Remission was associated with a lower risk of new and severe new damage; LDAS with a lower risk of new damage after adjusting for other damage confounders.
  • article 80 Citação(ões) na Scopus
    Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases
    (2011) SAAD, Carla G. S.; BORBA, Eduardo F.; AIKAWA, Nadia E.; SILVA, Clovis A.; PEREIRA, Rosa M. R.; CALICH, Ana Luisa; MORAES, Julio C. B.; RIBEIRO, Ana C. M.; VIANA, Vilma S. T.; PASOTO, Sandra G.; CARVALHO, Jozelio F.; FRANCA, Ivan L. A.; GUEDES, Lissiane K. N.; SHINJO, Samuel K.; SAMPAIO-BARROS, Percival D.; CALEIRO, Maria T.; GONCALVES, Celio R.; FULLER, Ricardo; LEVY-NETO, Mauricio; TIMENETSKY, Maria do Carmo S.; PRECIOSO, Alexander R.; BONFA, Eloisa
    Background Despite the WHO recommendation that the 2010-2011 trivalent seasonal flu vaccine must contain A/California/7/2009/H1N1-like virus there is no consistent data regarding its immunogenicity and safety in a large autoimmune rheumatic disease (ARD) population. Methods 1668 ARD patients (systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic sclerosis, psoriatic arthritis (PsA), Behcet's disease (BD), mixed connective tissue disease, primary antiphospholipid syndrome (PAPS), dermatomyositis (DM), primary Sjogren's syndrome, Takayasu's arteritis, polymyositis and Granulomatosis with polyangiitis (Wegener's) (GPA)) and 234 healthy controls were vaccinated with a non-adjuvanted influenza A/California/7/2009(H1N1) virus-like strain flu. Subjects were evaluated before vaccination and 21 days post-vaccination. The percentage of seroprotection, seroconversion and the factor increase in geometric mean titre (GMT) were calculated. Results After immunisation, seroprotection rates (68.5% vs 82.9% p < 0.0001), seroconversion rates (63.4% vs 76.9%, p < 0.001) and the factor increase in GMT (8.9 vs 13.2 p < 0.0001) were significantly lower in ARD than controls. Analysis of specific diseases revealed that seroprotection significantly reduced in SLE (p < 0.0001), RA (p < 0.0001), PsA (p=0.0006), AS (p=0.04), BD (p=0.04) and DM (p=0.04) patients than controls. The seroconversion rates in SLE (p < 0.0001), RA (p < 0.0001) and PsA (p=0.0006) patients and the increase in GMTs in SLE (p < 0.0001), RA (p < 0.0001) and PsA (p < 0.0001) patients were also reduced compared with controls. Moderate and severe side effects were not reported. Conclusions The novel recognition of a diverse vaccine immunogenicity profile in distinct ARDs supports the notion that a booster dose may be recommended for diseases with suboptimal immune responses. This large study also settles the issue of vaccine safety. (ClinicalTrials.gov #NCT01151644)
  • conferenceObject
    RNA-SEQUENCING OF CLASSICAL MONOCYTES FROM RHEUMATOID ARTHRITIS PATIENTS WITH AND WITHOUT BONE EROSION
    (2023) SALES, L. Peixoto; HOUNKPE, B.; PEREZ, M.; CAPARBO, V.; DOMICIANO, D. S.; BORBA, E.; FIGUEIREDO, C.; PEREIRA, R. M.
  • conferenceObject
    COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES ON CHRONIC USE OF HYDROXYCHLOROQUINE IN A LARGE BRAZILIAN COHORT - A 24-WEEK PROSPECTIVE STUDY
    (2021) PILEGGI, G. Salviato; FERREIRA, G.; GOMIDES, A. P.; REIS NETO, E.; ABREU, M.; ALBUQUERQUE, C.; ARAUJO, N.; BACCHIEGA, A. B.; BIANCHI, D.; BICA, B.; BONFA, E.; BORBA, E.; BRITO, D.; DUARTE, A.; SOUZA, M. Peixoto Gu e Silva de; GOMES, K. Wagner Poti; KAKEHASI, A. Maria; SANTO, R. Cavalheiro Do Espirito; REALLE, P.; KLUMB, E.; LANNA, C. C.; MARQUES, C.; MONTICIELO, O.; MOTA, L.; MUNHOZ, G.; PAIVA, E.; PEREIRA, H.; PROVENZA, J. R.; RIBEIRO, S.; ROCHA JR., L.; SAMPAIO, C.; SAMPAIO, V.; SATO, E.; SKARE, T. Laroca; SOUZA, V. De; VALIM, V.; LACERDA, M.; XAVIER, R.; PINHEIRO, M.
  • conferenceObject
    ACUTE AEROBIC EXERCISE INDUCES INCREASES ON PLASMA LEVELS OF alpha-MELANOCYTE STIMULATING HORMONE IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
    (2014) PERANDINI, L.; GUALANO, B.; PINTO, A. L. D. S.; LIMA, F.; BONFA, E.; BORBA, E. F.; ROSCHEL, H.; MELLO, S. B.
  • conferenceObject
    PREDICTORS OF FIRST HOSPITALIZATIONS DUE TO DISEASE ACTIVITY AND INFECTIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
    (2023) QUINTANA, R.; NIETO, R.; MORALES, R. Serrano; UGARTE-GIL, M. F.; HARVEY, G. B.; WOJDYLA, D.; GOMEZ-PUERTA, J. A.; GARCIA, M.; CATOGGIO, L.; SAURIT, V.; DRENKARD, C.; SILVA, N. Da; CAVALCANTI, F.; BORBA, E.; SATO, E.; NEIRA, O.; MASSARDO, L.; VASQUEZ, G.; GONZALEZ, L. A.; GUIBERT-TOLEDANO, M.; TORRE, L. H. Silveira; TORRE, I. Garcia-De La; POZO, M. J. Sauza Del; CHACON, R.; ALARCON, G. S.; ORILLION, A.; SBARIGIA, U.; ZAZZETTI, F.; PONS-ESTEL, B.; PONS-ESTEL, G.
  • conferenceObject
    PREGNANCY OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): DATA FROM A MULTIETHNIC, MULTINATIONAL LATIN AMERICAN COHORT
    (2023) MORALES, R. M. Serrano; NIETO, R.; QUINTANA, R.; ALBA, P.; PORTA, S.; HERNANDEZ, L.; BERBOTTO, G.; BELLOMIO, V. I.; SILVA, N. Da; MONTICIELO, O.; CAVALCANTI, F.; RIBEIRO, F. Machado; BORBA, E.; BONFA, E.; MASSARDO, L.; MARTINEZ, G. Aroca; BONFANTI, A. Cadena; LOPEZ, G. Quintana; ALVAREZ, M. J. Moreno; VALERIO, J. A. Esquivel; ACOSTA-COLMAN, I.; PAATS, A.; MORA, C.; SCOLNIK, M.; AVILA, D. Fernandez; SOAJE, C. Funes; SAURIT, V.; GARCIA, M.; KERZBERG, E.; GOMEZ, G.; PISONI, C.; REIS NETO, E.; HERRERA, I. Guerra; NEIRA, O.; CANAS, C.; SAAVEDRA, M. A.; PORTELA, M.; LOYO, H. Fragoso; TORRE, L. H. Silveira; TORRE, I. Garcia-De la; UGARTE-GIL, M. F.; QUIROZ, A. Calvo; LOUIS, R. Munoz; ROBAINA, R.; JUAREZ, V.; DANZA, A.; GUTIERREZ, C. E. Toro; ABUD-MENDOZA, C.; MALVAR, A.; ALARCON, G. S.; ORILLION, A.; SBARIGIA, U.; ZAZZETTI, F.; PONS-ESTEL, G.; PONS-ESTEL, B.
  • conferenceObject
    INCREASED CORTICOTROPIN-RELEASING HORMONE (CRH) EXPRESSION IN CUTANEOUS LUPUS LESIONS
    (2014) SCHMITZ, M.; BOTTE, D. C.; BONFA, E.; BORBA, E. F.; MELLO, S. B.
  • article 88 Citação(ões) na Scopus
    First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR)
    (2018) PONS-ESTEL, Bernardo A.; BONFA, Eloisa; SORIANO, Enrique R.; CARDIEL, Mario H.; IZCOVICH, Ariel; POPOFF, Federico; CRINITI, Juan M.; VASQUEZ, Gloria; MASSARDO, Loreto; DUARTE, Margarita; BARILE-FABRIS, Leonor A.; GARCIA, Mercedes A.; AMIGO, Mary-Carmen; ESPADA, Graciela; CATOGGIO, Luis J.; SATO, Emilia Inoue; LEVY, Roger A.; VASQUEZ, Eduardo M. Acevedo; CHACON-DIAZ, Rosa; GALARZA-MALDONADO, Claudio M.; GAMARRA, Antonio J. Iglesias; MOLINA, Jose Fernando; NEIRA, Oscar; SILVA, Clovis A.; PENA, Andrea Vargas; GOMEZ-PUERTA, Jose A.; SCOLNIK, Marina; PONS-ESTEL, Guillermo J.; UGOLINI-LOPES, Michelle R.; SAVIO, Veronica; DRENKARD, Cristina; ALVARELLOS, Alejandro J.; UGARTE-GIL, Manuel F.; BABINI, Alejandra; CAVALCANTI, Andre; LINHARES, Fernanda Athayde Cardoso; SALINAS, Maria Jezabel Haye; FUENTES-SILVA, Yurilis J.; SILVA, Ana Carolina Montandon de Oliveira e; GARNICA, Ruth M. Eraso; URIBE, Sebastian Herrera; GOMEZ-MARTIN, Diana; SEVRINI, Ricardo Robaina; QUINTANA, Rosana M.; GORDON, Sergio; FRAGOSO-LOYO, Hilda; ROSARIO, Violeta; SAURIT, Veronica; APPENZELLER, Simone; REIS NETO, Edgard Torres dos; CIEZA, Jorge; NARANJO, Luis A. Gonzalez; BELLO, Yelitza C. Gonzalez; COLLADO, Maria Victoria; SARANO, Judith; RETAMOZO, Soledad; SATTLER, Maria E.; GAMBOA-CARDENAS, Rocio V.; CAIROLI, Ernesto; CONTI, Silvana M.; AMEZCUA-GUERRA, Luis M.; SILVEIRA, Luis H.; BORBA, Eduardo F.; PERA, Mariana A.; MOREYRA, Paula B. Alba; ARTURI, Valeria; BERBOTTO, Guillermo A.; GERLING, Cristian; GOBBI, Carla A.; GERVASONI, Viviana L.; SCHERBARTH, Hugo R.; BRENOL, Joao C. Tavares; CAVALCANTI, Fernando; COSTALLAT, Lilian T. Lavras; SILVA, Nilzio A. Da; MONTICIELO, Odirlei A.; SEGURO, Luciana Parente Costa; XAVIER, Ricardo M.; LLANOS, Carolina; GUARDADO, Ruben A. Montufar; TORRE, Ignacio Garcia de la; PINEDA, Carlos; HERNANDEZ, Margarita Portela; DANZA, Alvaro; GUIBERT-TOLEDANO, Marlene; REYES, Gil Llerena; COLMAN, Maria Isabel Acosta; AQUINO, Alicia M.; MORA-TRUJILLO, Claudia S.; MUNOZ-LOUIS, Roberto; VALLADARES, Ignacio Garcia; OROZCO, Maria Celeste; BURGOS, Paula I.; BETANCUR, Graciela V.; ALARCON, Graciela S.
    Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an 'overarching' treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings.
  • article 74 Citação(ões) na Scopus
    Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice
    (2011) RIBEIRO, Ana C. M.; GUEDES, Lissiane K. N.; MORAES, Julio C. B.; SAAD, Carla G. S.; AIKAWA, Nadia E.; CALICH, Ana Luisa; FRANCA, Ivan L. A.; CARVALHO, Jozelio F.; SAMPAIO-BARROS, Percival D.; GONCALVES, Celio R.; BORBA, Eduardo F.; TIMENETSKY, Maria do Carmo S.; PRECIOSO, Alexander R.; DUARTE, Alberto; BONFA, Eloisa; LAURINDO, Ieda M. M.
    Background Reduced response to pandemic (2009) H1N1 (pH1N1) vaccine in patients with rheumatoid arthritis (RA) was recently reported. Objectives To evaluate the contribution of age, disease activity, medication and previous antibody levels to this reduced response. Methods 340 adult RA patients and 234 healthy controls were assessed before and 21 days after adjuvant-free influenza A/California/7/2009 (pH1N1) vaccine. Disease activity (DAS28), current treatment and pH1N1 antibody titres were collected. Seroprotection, seroconversion and factor increase in geometric mean titre (GMT) were calculated and adverse events registered. Results RA and controls showed similar (p> 0.05) prevaccination GMT (8.0 vs 9.3) and seroprotection (10.8% vs 11.5%). After vaccination a significant reduction (p< 0.001) was observed in all endpoints: GMT and factor increase in GMT, seroprotection and seroconversion rates. Disease activity did not preclude seroconversion or seroprotection and remained unchanged in 97.4% of patients. Methotrexate was the only disease-modifying antirheumatic drug associated with reduced responses (p= 0.001). Vaccination was well tolerated. Conclusions The data confirmed both short-term anti-pH1N1 vaccine safety and, different from most studies with seasonal influenza, reduced seroprotection in RA patients, unrelated to disease activity and to most medications (except methotrexate). Extrapolation of immune responses from one vaccine to another may therefore not be possible and specific immunisation strategies (possibly booster) may be needed.